Eli Lilly has entered into a global research and licensing agreement with Seamless Therapeutics to develop programmable recombinase-based gene editing treatments for inherited hearing loss. Under the deal, Seamless will receive over $1.12 billion in upfront payments, R&D funding and potential milestones, while Lilly secures exclusive rights to advance the site-specific recombinases through preclinical and clinical development into commercialization. The collaboration combines Seamless’ proprietary platform—capable of large, precise DNA insertions independent of natural repair pathways—with Lilly’s expertise in genetic hearing disorders, positioning the companies to address a high unmet medical need in defined hearing loss indications.

In the most recent quarter, Alta Wealth Advisors LLC reduced its position in Eli Lilly by 17.0%, selling 522 shares and ending the period with 2,541 shares valued at approximately $1.94 million. This move contributes to the broader reshaping of the company’s shareholder base, where institutional and hedge fund ownership stands at over 82%. Notable activity among other firms includes Sumitomo Mitsui Financial Group’s initial stake acquisition valued at $27,000 and Bare Financial Services increasing its holding by 263.6% to 40 shares, underscoring varied investor sentiment across the spectrum.

For its third quarter, Lilly reported earnings per share of $7.02, topping consensus estimates by $0.60, and generated revenue of $17.60 billion, a 53.9% increase year-over-year and above the $16.09 billion analysts expected. The company’s net margin reached 30.99% and return on equity climbed to 109.52%. Management set full-year 2025 EPS guidance between 23.00 and 23.70, in line with a $23.48 market consensus. In parallel, the board approved a quarterly dividend of $1.73 (annualized at $6.92) with a payout ratio of 29.35%. Among research firms, four have a Strong Buy rating, eighteen rate the stock as Buy and four as Hold, yielding an average target price of $1,174.61.